Hand-foot Syndrome Clinical Trial
Official title:
The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome in Breast Cancer Patients: A Multicenter, Phase III, Randomized, Double-blind, Controlled Trial
A multicenter, randomized, placebo-controlled, double-blind, phase III clinical trial will be conducted to explore the efficacy and safety of mecobalamin in the prevention of 2/3 HFS in patients with early breast cancer. 234 patients will be enrolled and will be randomized into mecobalamin group and placebo group at the ration of 1:1. The incidence of grade 2 / 3 HFS in the experimental group and the control group will be observed. This study is expected to provide evidence for clinical prevention of hand foot syndrome, improve clinical treatment guidelines for early breast cancer, and provide reference for other antitumor drugs for hand foot syndrome.
Capecitabine is a drug recommended for adjuvant therapy in early breast cancer. The key to improving the prognosis of early breast cancer is to ensure that adequate treatment is sufficient. Hand foot syndrome Hand foot syndrome (HFS) is the most common and specific side effect of capecitabine, in which the incidence of grade 2 / 3 HFS requiring treatment is as high as 17-36%. At present, there is no specific drug for the treatment of HFS, and capecitabine must be reduced or stopped in case of grade 2 / 3 HFS. The guidelines also do not recommend standard drugs for the prevention of HFS. Mecobalamin is a derivative of vitamin B12, which can improve autonomic nervous system After symptoms and repair of small neuropathy, its clinical indication is the treatment of peripheral neuropathy. A multicenter, randomized, placebo-controlled, double-blind, phase III clinical trial will be conducted to explore the efficacy and safety of mecobalamin in the prevention of 2/3 HFS in patients with early breast cancer. 234 patients will be enrolled and will be randomized into mecobalamin group and placebo group at the ration of 1:1. The incidence of grade 2 / 3 HFS in the experimental group and the control group will be observed. This study is expected to provide evidence for clinical prevention of hand foot syndrome, improve clinical treatment guidelines for early breast cancer, and provide reference for other antitumor drugs for hand foot syndrome. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04592731 -
Acetylated Natural Nucleotides in Treating Hand-foot Syndrome
|
N/A | |
| Completed |
NCT05755646 -
Ice Plant Intensive Cream for the Prevention of Hand-Foot Syndrome in Breast Cancer: Pilot Randomized Controlled Trial
|
N/A | |
| Completed |
NCT00446147 -
Study of Pyridoxine for Hand-Foot Syndrome
|
Phase 3 | |
| Completed |
NCT01609166 -
Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome
|
Phase 2 | |
| Terminated |
NCT03173365 -
The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients
|
Phase 2 | |
| Recruiting |
NCT04979078 -
Photobiomodulation Therapy in the Management of Hand-foot Syndrome and Hand-foot Skin Reaction
|
N/A | |
| Recruiting |
NCT05348278 -
Urea Cream Prevention for Capecitabine Associated Hand Foot Syndrome
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04833998 -
Hydration Based on Thoitaine, Aloe Vera and Calendula, in the Prevention of Hand-Foot Syndrome in Patients Using Capecitabine
|
Phase 2 | |
| Not yet recruiting |
NCT05949307 -
The Efficacy of Acupuncture and Laser Acupuncture in Treating Chemotherapy or Target Therapy-induced Hand-foot Syndrome
|
N/A |